Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to ImatinibHélène Labussière, Franck E. Nicolini, Joëlle Bernard et al.|Blood|2008Cited by 11
Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patientsMauricette Michallet, Sandrine Hayette, Mohamad Sobh et al.|Blood|2008Cited by 0
Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot StudyMarie Y. Detrait, Mauricette Michallet, Mohamad Sobh et al.|Blood|2012Cited by 0